drugset
Drugs / FIBOFLAPON
last change Dec 2014 re-read 2 minutes ago

FIBOFLAPON

also known as GSK2190915 · AM-803 · AM-803 SODIUM · CHEMBL1922660 · FIBOFLAPON SODIUM · GSK2190915A · GSK2190915B · SODIUM SALT

Small molecule targets ALOX5AP via inhibition

Developed for
asthma
Investigated by
GlaxoSmithKline

Trials 11 · a red edge is where a trial was stopped

today NCT01471665 · Ph 2 NCT01248975 · Ph 2 NCT01286844 · Ph 2 NCT01318980 · Ph 1 NCT01721135 · Ph 1 NCT01156792 · Ph 2 NCT01147744 · Ph 2 NCT02224521 · Ph 1 NCT00748306 · Ph 2 NCT00812773 · Ph 2 NCT00812929 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT01318980 Sep 2010 → Mar 2011 asthma GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT01721135 Sep 2010 → Dec 2014 asthma GlaxoSmithKline Withdrawn No outcome recorded
Phase 1 NCT02224521 Apr 2009 → Jun 2010 asthma GlaxoSmithKline Completed No outcome recorded
Phase 28 trials
Phase 2 NCT01471665 Jun 2011 → May 2012 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01248975 Dec 2010 → Oct 2011 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01286844 Nov 2010 → May 2011 asthma GlaxoSmithKline Withdrawn No outcome recorded
Phase 2 NCT01156792 Sep 2010 → Oct 2011 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01147744 Jun 2010 → Oct 2011 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00812929 Dec 2008 → Jun 2009 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00748306 Dec 2008 → Sep 2009 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00812773 Dec 2008 → Jul 2009 asthma GlaxoSmithKline Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01411111 Comparator Jan → Feb 2011 asthma GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00955383 Comparator Aug → Oct 2009 asthma GlaxoSmithKline Completed No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as FIBOFLAPON ChEMBL registry synonym — accepted as the source's own label CHEMBL1922660 ↗
Known as AM-803 ChEMBL registry synonym — accepted as the source's own label CHEMBL1922660 ↗
Known as AM-803 SODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL1922660 ↗
Known as CHEMBL1922660 ChEMBL registry synonym — accepted as the source's own label CHEMBL1922660 ↗
Known as FIBOFLAPON SODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL1922660 ↗
Known as GSK2190915 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01471665 ↗
11

NCT00812929 ↗

NCT01147744 ↗

NCT01411111 ↗

NCT00955383 ↗

NCT02224521 ↗

NCT00748306 ↗

NCT00812773 ↗

NCT01318980 ↗

NCT01721135 ↗

NCT01248975 ↗

NCT01156792 ↗
Known as GSK2190915A ClinicalTrials.gov intervention name — accepted as the source's own label NCT01286844 ↗
Known as GSK2190915B ChEMBL registry synonym — accepted as the source's own label CHEMBL1922660 ↗
Known as SODIUM SALT ChEMBL registry synonym — accepted as the source's own label CHEMBL1922660 ↗
Action Inhibit “5-lipoxygenase activating protein inhibitor” CHEMBL1922660 ↗
1

“FLAP inhibitor” NCT00748306 ↗
Modality Small molecule — CHEMBL1922660 ↗
Route Oral “repeat oral doses of GSK2190915” NCT00812773 ↗
Target ALOX5AP “5-lipoxygenase activating protein inhibitor” CHEMBL1922660 ↗